Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

The oral drug candidate aims to rival Sanofi and Regeneron’s blockbuster therapy, Dupilumab, which recorded $11.6 billion in global sales in 2023. The trial tested the safety and efficacy of ...

Sanofi and Regeneron have reported that the Phase III AERIFY ... In 2023, the companies reported positive interim data from the Phase III NOTUS trial with Dupixent (dupilumab), showing a 34% decrease ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

This includes Dupixent® (dupilumab), Libtayo® (cemiplimab ... the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and ...